Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 6

Mide kanseri dokularında yüksek çözünürlüklü erime eğrisi analizi ile dihidroprimidin dehidrogenaz geninde T85C polimorfizmi tespit edilmiştir

T85C polymorphisms of the dihydropyrimidine dehydrogenase gene detected in gastric cancer tissues by high-resolution melting curve analysis

Pages
652–657
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Real-time polymerase chain reaction combined with high-resolution melting curve technology is a rapid, simple, reliable, direct-viewing, and convenient method for the detection and screening of polymorphisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Dihydropyrimidine dehydrogenase is a key enzyme acting on the metabolic pathway of medications for gastric cancer.
📊
Key Findings & Data:Materials and Methods: T85C polymorphisms of dihydropyrimidine dehydrogenase in the peripheral blood of 112 Chinese gastric cancer patients were detected by real-time polymerase chain reaction combined with high-resolution melting curve technology.
💡
Conclusion & Impact:Conclusions: Real-time polymerase chain reaction combined with high-resolution melting curve technology is a rapid, simple, reliable, direct-viewing, and convenient method for the detection and screening of polymorphisms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: Dihydropyrimidine dehydrogenase is a key enzyme acting on the metabolic pathway of medications for gastric cancer. High-resolution melting curve technology, which was developed recently, can distinguish the wild-type dihydropyrimidine dehydrogenase gene from multiple polymorphisms by fluorescent quantitative polymerase chain reaction products in a direct and effective manner. Materials and Methods: T85C polymorphisms of dihydropyrimidine dehydrogenase in the peripheral blood of 112 Chinese gastric cancer patients were detected by real-time polymerase chain reaction combined with high-resolution melting curve technology. Primer design, along with the reaction system and conditions, was optimized based on the GenBank sequence. Results: Seventy nine cases of wild-type (TT, [70.5%]), 29 cases of heterozygous (TC, [25.9%]), and 4 cases of homozygous mutant (CC, [3.6%]) were observed. The result was completely consistent with the results of the sequencing. Conclusions: Real-time polymerase chain reaction combined with high-resolution melting curve technology is a rapid, simple, reliable, direct-viewing, and convenient method for the detection and screening of polymorphisms.

Özet

Giriş ve Amaç: Dihidroprimidin dehidrogenaz mide kanserinde kullanılan tedavilerin metabolizması için anahtar role sahip bir enzimdir. Yeni geliştirilen, yüksek çözünürlüklü erime eğrisi teknolojisi, doğal tip dihidroprimidin dehidrogenaz geni ile çoklu polimorfizmini, flöresan ile kantifiye zincirleme polimeraz reaksiyonu kullanarak doğrudan ve etkin bir şekilde ayırabilir. Gereç ve Yöntem: Dihidroprimidin dehidrogenaz T85C polimorfizmi 112 Çinli mide kanseri hastasının periferik kanında gerçek zamanlı zincirleme polimeraz reaksiyonu ve yüksek çözünürlüklü erime eğrisi teknolojisi kullanılarak tespit edildi. Primer üretimi, reaksiyon sistemi ve koşulları GenBank sekansı dikkate alınarak optimize edildi. Bulgular: Doğal tip 79 vakada (TT; %70.5), heterozigot 29 vakada (TC; %25,9) ve homozigot mutasyon 4 vakada (cc; %3,6) tespit edildi. Sonuçların sekans analizi ile tam uyumlu olduğu görüldü. Sonuç: Gerçek zamanlı zincirleme polimeraz reaksiyonu ile yüksek çözünürlüklü erime eğrisi teknolojisinin kombine edilmesi polimorfizmlerin tespit edilmesinde hızlı, kolay, güvenilir, doğrudan gözlemlenebilir bir yöntemdir.

🔖

Cite This Article

FANG, W., XU, N., JIN, D., CHEN, Y., CHEN, X., ZHENG, Y., SHEN, H., YUAN, Y., ZHENG, S. (2012). Mide kanseri dokularında yüksek çözünürlüklü erime eğrisi analizi ile dihidroprimidin dehidrogenaz geninde T85C polimorfizmi tespit edilmiştir. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 6, 652–657. https://ajindex.com/articles/410328

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. Atlanta: American Cancer Society
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49. 3. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyridine dehydrogenase deficiency. Ann Clin Biochem 2003; (40): 41
  3. Van Kuilenburg AB, Vreken P, Abeling NG, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9
  4. Cai L, Zhu Z. Dihydropyrimidine dehydrogenase (DPD) and its relation with efficacy and toxicity of 5-fluorouracil. Chin Pharm J 2007; 42: 1441-5
  5. Gamelin E, Boisdron-Celle M, Guérin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105-10
  6. Jiang H, Lu J, Jiang J, Hu P. Important role of the dihydrouracil/ uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2004; 44: 1260-72
  7. Maring JG, Groen HJ, Wachters FM, et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics 2005; 5: 226-43
  8. Uetake H, Ichikawa W, Takechi T, et al. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999; 5: 2836-9
  9. Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46: 151-6
  10. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning 2008; 29-449
  11. Balhana R, Stoker NG, Sikder MH, et al. Rapid construction of mycobacterial mutagenesis vectors using ligation-independent cloning, RF cloning. J Microbiol Methods 2010; 83: 34-41
  12. Brown PO, Hartwell L. Genomics and human disease-- variations on variation. Nat Genet 1998; 18: 91-3
  13. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91
  14. Nagoya J. Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. Med Sci 2005; 67: 117-24
  15. Gao CM, Takezaki T, Wu JZ, et al. Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susce